Recent Updates
Recently added Catalysts

Dystrophic Epidermolysis Bullosa: one US-listed biotech with a clinical-stage programme

Rare Genetic & MetabolicUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$11.0Buniverse median $1.20B
Allocated capital$2.2B$11.0B competing
Phase 3 or filed10 mid, 0 early
Pure plays0this indication only
Capital rank91/299crowding rank 120

Dystrophic Epidermolysis Bullosa is uncontested. Krystal Biotech (KRYS) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with KB803 in phase 3.

There is no public comparable to price it against. KRYS spreads its $11.0B market cap across 5 indications, so $2.2B of it is allocated here.

The one programme here is in late-stage development, with 1 dated catalyst in the next 12 months.

$2.2B of allocated capital sits in Dystrophic Epidermolysis Bullosa, ranking it 91st of 299 indications by the money committed to it.

Companies developing drugs for Dystrophic Epidermolysis Bullosa 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
KRYSKrystal BiotechKB803Phase 31$11.0BNo5 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Dystrophic Epidermolysis Bullosa counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Dystrophic Epidermolysis Bullosa has one competitor and a median of $11.0B.

Rare Genetic & Metabolic

Rare Genetic & Metabolic holds $103B of the map's capital, 15.3% of the total, spread across 32 indications and 48 companies. 10 of those indications have more than one company competing.

See every Rare Genetic & Metabolic indication on the map

Related indications in Rare Genetic & Metabolic

Cystic Fibrosis4 companies · $3.1B · median $605MOrphan cornerAcquired Angioedema1 company · $1.2B · median $2.3BUncontestedMECP2 Duplication Syndrome1 company · $1.1B · median $9.7BUncontestedVon Willebrand Disease1 company · $1.0B · median $2.1BUncontestedCongenital FVII Deficiency1 company · $1.0B · median $2.1BUncontestedAntithrombin III Deficiency1 company · $1.0B · median $2.1BUncontestedFacioscapulohumeral Muscular Dystrophy2 companies · $3.5B · median $3.5BConcentrated betLimb-Girdle Muscular Dystrophy1 company · $809M · median $2.4BUncontested

Dystrophic Epidermolysis Bullosa pipeline questions

Which biotech companies are developing drugs for Dystrophic Epidermolysis Bullosa?

Krystal Biotech (KRYS, KB803, Phase 3). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Dystrophic Epidermolysis Bullosa.

How advanced is the Dystrophic Epidermolysis Bullosa pipeline?

Of the 1 clinical-stage programme in Dystrophic Epidermolysis Bullosa, 1 is in Phase 3 or filed, 0 are in mid-stage development and 0 are in early-stage development.

Is anyone else developing a drug for Dystrophic Epidermolysis Bullosa?

No. KRYS is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Dystrophic Epidermolysis Bullosa, which is why the indication is classified as uncontested.

When is the next Dystrophic Epidermolysis Bullosa catalyst?

The next dated catalyst in Dystrophic Epidermolysis Bullosa is KRYS on 31 Dec 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map